US 12,281,147 B2
Interleukin 21 variants
Davis Goodnight, Seattle, WA (US); Emily Engelhart, Seattle, WA (US); and Ryan Swanson, Seattle, WA (US)
Assigned to A-Alpha Bio, Inc., Seattle, WA (US)
Filed by A-Alpha Bio, Inc., Seattle, WA (US)
Filed on Aug. 14, 2024, as Appl. No. 18/804,738.
Claims priority of provisional application 63/574,538, filed on Apr. 4, 2024.
Claims priority of provisional application 63/519,389, filed on Aug. 14, 2023.
Prior Publication US 2025/0059247 A1, Feb. 20, 2025
Int. Cl. C07K 14/54 (2006.01); C07K 16/28 (2006.01)
CPC C07K 14/54 (2013.01) [C07K 16/28 (2013.01); C07K 2319/33 (2013.01)] 19 Claims
 
1. A human interleukin 21 (IL-21) variant, wherein the IL-21 variant comprises a polypeptide sequence as set forth in any one of SEQ ID NOs: 462, 463, 1192, 950, 933, and 894, or comprises one or more amino acid substitutions at one or more positions of SEQ ID NO: 1 selected from the group consisting of R38W and R105W.